5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid amide | 1345041-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid amide
• 英文别名: 3-(4-Chlorophenyl)-2-phenyl-3,4-dihydropyrazole-5-carboxamide
• CAS: 1345041-79-3
• 化学式: C₁₆H₁₄ClN₃O
• 分子量: 299.76
• InChiKey: JZTJFWQFGCCNNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid amide 在 草酰氯 、 二正丁基氧化锡 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 4.33h， 生成 5-[5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-2H-tetrazole
  参考文献：
  名称：

  Synthesis and anti-inflammatory activity of some new 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazole derivatives

  摘要：

  A series of 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazoles were designed and synthesized in order to obtain new compounds with potential anti-inflammatory activity. The title compounds were screened for in vivo anti-inflammatory activity by using Carrageenan induced rat paw edema method. Diclofenac sodium was used as a standard drug for comparison. Out of the 30 compounds tested, compound 19a, 19b, 25a, 25b exhibited significant anti-inflammatory activity. Selected compounds were also screened for in vitro COX-2 inhibition assay and analgesic activity in the acetic acid induced writhing model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.061
• 作为产物：
  描述：

  potassium 4-(4-chlorophenyl)-2-oxobut-3-enoate 在 氯化亚砜 、 Ammonium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 12.0h， 生成 5-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid amide
  参考文献：
  名称：

  Synthesis and anti-inflammatory activity of some new 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazole derivatives

  摘要：

  A series of 4,5-dihydro-1,5-diaryl-1H-pyrazole-3-substituted-heteroazoles were designed and synthesized in order to obtain new compounds with potential anti-inflammatory activity. The title compounds were screened for in vivo anti-inflammatory activity by using Carrageenan induced rat paw edema method. Diclofenac sodium was used as a standard drug for comparison. Out of the 30 compounds tested, compound 19a, 19b, 25a, 25b exhibited significant anti-inflammatory activity. Selected compounds were also screened for in vitro COX-2 inhibition assay and analgesic activity in the acetic acid induced writhing model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.061

文献信息

• [EN] SUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES AS CANNABINOID MODULATORS<br/>[FR] DÉRIVÉS DE 4,5-DIHYDRO-1H-PYRAZOLE SUBSTITUÉS COMME MODULATEURS DE CANNABINOÏDES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2008062424A2

  公开（公告）日：2008-05-29

  [EN] Disclosed herein in the embodiment of the invention are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also discloses process of preparing compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
  [FR] L'invention concerne, dans un mode de réalisation, des composés de formule générale (I), leurs stéréoisomères, régioisomères, formes tautomères et nouveaux intermédiaires mis en jeu dans leur synthèse, leurs sels pharmaceutiquement actifs, leurs solvates pharmaceutiquement acceptables et les compositions pharmaceutiques les contenant. La présente invention porte également sur un procédé de fabrication de composés de la formule générale (I), leurs stéréoisomères, régioisomères, leurs formes tautomères, leurs sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables, compositions pharmaceutiques les contenant et nouveaux intermédiaires mis en jeu dans leur synthèse.